CLSN - セルシオン (Celsion Corporation) セルシオン

 CLSNのチャート


 CLSNの企業情報

symbol CLSN
会社名 Celsion Corp (セルシオン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 セルシオン(Celsion Corporation)は治療が難しい癌の患者向けの治療法の開発するを中心とする腫瘍薬品の開発企業。平成23年12月31日現在、同社の主力商品「ThermoDox」は、肝臓癌に対する「HEAT」研究と呼ばれる第3相臨床試験、大腸癌の肝臓転移に対する第2相臨床研究及び再発性胸壁乳癌に対する第2相臨床研究において評価されている。「ThermoDox」はリポソームカプセル化したドキソルビシンであり、各種癌の治療でよく使用される認可を受けた腫瘍薬品である。軽度の温熱療法でのローカライズされた熱はリポソームから封入ドキソルビシンを放出して、高濃度のドキソルビシンが対象となる腫瘍またはその周辺で優先的に堆積されることを可能にする。リポソームは、超顕微鏡で製造された小胞体であり、自然に発生する脂肪が含まれる膜二重層に囲まれた離散的な水系中心コンパートメントを含む。   セルシオンは、米国の医薬品開発会社。癌に苦しむ人々の治療法を開発する。独自の熱活性化リポソ―ム技術をベ―スにタ―ゲットを絞った化学療法腫瘍薬を開発し、商品化に取り組む。主要製品である癌治療薬「サ―モドックス」は、原発性肝癌を対象とした第3相臨床試験と、再発胸壁の乳癌治療を対象にした第2相臨床試験で評価されている。   Celsion Corp . is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
本社所在地 997 Lenox Drive Suite 100 Lawrenceville NJ 08648 USA
代表者氏名 Jeffrey Wayne Church ジェフリー・ウェイン教会
代表者役職名 Chief Financial Officer Senior Vice President Corporate Secretary IR Contact Officer
電話番号 +1 609-896-9100
設立年月日 30072
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 19人
url www.celsion.com
nasdaq_url https://www.nasdaq.com/symbol/clsn
adr_tso
EBITDA EBITDA(百万ドル) -20.93515
終値(lastsale) 2.65
時価総額(marketcap) 47027655.25
時価総額 時価総額(百万ドル) 44.59869
売上高 売上高(百万ドル) 0.50000
企業価値(EV) 企業価値(EV)(百万ドル) 27.62501
当期純利益 当期純利益(百万ドル) -23.05973
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Celsion Corporation revenues remained flat at $250K. Net loss applicable to common stockholders increased 22% to $12.7M. Revenues reflect market conditions. Higher net loss reflects Selling General_Administrative increase of 67% to $5.2M (expense) Research and development increase of 12% to $7.3M (expense) Other (expense) income decrease from $3K (income) to $0K.

 CLSNのテクニカル分析


 CLSNのニュース

   Celsion (NASDAQ:CLSN) Lowered to Strong Sell at Zacks Investment Research  2020/11/20 12:46:50 Transcript Daily
Zacks Investment Research downgraded shares of Celsion (NASDAQ:CLSN) from a hold rating to a strong sell rating in a research note published on Thursday morning, Zacks.com reports. According to Zacks, “Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery […]
   ROSEN, LEADING INVESTOR COUNSEL, Reminds Celsion Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – CLSN - Stocks News Feed  2020/11/13 19:46:00 Stocks News Feed
NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the “Class Period”), of the important December 29, 2020 lead plaintiff deadline in the securities class action. The lawsuit… Read More »ROSEN, LEADING INVESTOR COUNSEL, Reminds Celsion Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – CLSN
   CLSN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Celsion Corporation Shareholders With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: December 28, 2020  2020/11/13 16:00:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against of Celsion Corporation ("Celsion" or "the Company") (NASDAQ: CLSN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Celsion securities between November 2, 2015 to July 10, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/clsn. Th
   CLSN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Celsion Corporation Shareholders of Class Action and Lead Plaintiff Deadline: December 28, 2020 - Stocks News Feed  2020/11/11 16:00:00 Stocks News Feed
NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against of Celsion Corporation (“Celsion” or “the Company”) (NASDAQ: CLSN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Celsion securities between November 2, 2015 to… Read More »CLSN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Celsion Corporation Shareholders of Class Action and Lead Plaintiff Deadline: December 28, 2020
   ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Reminds Celsion Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - CLSN  2020/11/10 00:30:00 Benzinga
NEW YORK , Nov. 9, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN ) between November 2, 2015 and July 10, 2020 , inclusive (the "Class Period"), of the important December 29, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Celsion investors under the federal securities laws. To join the Celsion class action, go to http://www.rosenlegal.com/cases-register-1978.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email Full story available on Benzinga.com
   ROSEN, LEADING INVESTOR COUNSEL, Reminds Celsion Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – CLSN - Stocks News Feed  2020/11/13 19:46:00 Stocks News Feed
NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the “Class Period”), of the important December 29, 2020 lead plaintiff deadline in the securities class action. The lawsuit… Read More »ROSEN, LEADING INVESTOR COUNSEL, Reminds Celsion Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – CLSN
   CLSN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Celsion Corporation Shareholders With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: December 28, 2020  2020/11/13 16:00:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against of Celsion Corporation ("Celsion" or "the Company") (NASDAQ: CLSN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Celsion securities between November 2, 2015 to July 10, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/clsn. Th
   CLSN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Celsion Corporation Shareholders of Class Action and Lead Plaintiff Deadline: December 28, 2020 - Stocks News Feed  2020/11/11 16:00:00 Stocks News Feed
NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against of Celsion Corporation (“Celsion” or “the Company”) (NASDAQ: CLSN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Celsion securities between November 2, 2015 to… Read More »CLSN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Celsion Corporation Shareholders of Class Action and Lead Plaintiff Deadline: December 28, 2020
   ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Reminds Celsion Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - CLSN  2020/11/10 00:30:00 Benzinga
NEW YORK , Nov. 9, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN ) between November 2, 2015 and July 10, 2020 , inclusive (the "Class Period"), of the important December 29, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Celsion investors under the federal securities laws. To join the Celsion class action, go to http://www.rosenlegal.com/cases-register-1978.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email Full story available on Benzinga.com
   SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Celsion Corporation of Class Action Lawsuit and Upcoming Deadline – CLSN - Stocks News Feed  2020/11/07 22:22:35 Stocks News Feed
NEW YORK, Nov. 07, 2020 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation (“Celsion” or the “Company”) (NASDAQ:CLSN). The class action, filed in United States District Court for the District of New Jersey, and docketed under 20-cv-015228, is on behalf of a class… Read More »SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Celsion Corporation of Class Action Lawsuit and Upcoming Deadline – CLSN
   Celsion Corporation to Hold Second Quarter 2020 Financial Results and Business Update Conference Call on Friday, August 14, 2020  2020/08/07 12:30:00 GlobeNewswire
LAWRENCEVILLE, N.J, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to…
   Celsion among healthcare gainers; Aurinia Pharmaceuticals and BioNTech among losers  2020/07/23 15:04:53 Seeking Alpha
Gainers: Milestone Pharmaceuticals MIST +137%. CymaBay Therapeutics CBAY +34%. Entera Bio ENTX +31%. Celsion (NASDAQ:CLSN) +27%. AMAG Pharmaceuticals AMAG
   Celsion (CLSN) Stock Loses a Wall Street Supporter  2020/07/18 02:26:39 Smarter Analyst
Stocks go up, stocks go down, you can’t explain that… Or maybe you can, if the stock happen to be a biotech that just … The post Celsion (CLSN) Stock Loses a Wall Street Supporter appeared first on Smarter Analyst .
   Vaxart and Benefytt Technologies among healthcare gainers; Celsion leads the losers  2020/07/13 15:02:37 Seeking Alpha
Gainers: Equillium EQ +155%. NovaBay Pharmaceuticals NBY +50%. Benefytt Technologies BFYT +38%. Vaxart (NASDAQ:VXRT) +31%. BiondVax Pharmaceuticals (NASDAQ
   Celsion Corporation Announces Closing of Public Offering of Common Stock  2020/06/24 20:15:00 GlobeNewswire
Lawrenceville, NJ, June 24, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 セルシオン CLSN Celsion Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)